Akorn, Inc. (NASDAQ:AKRX) price target set to $9.00 by Royal Bank of Canada

ME Staff
-
0

Analyst Ratings For Akorn, Inc. (NASDAQ:AKRX)

Today, Royal Bank of Canada set its price target on Akorn, Inc. (NASDAQ:AKRX) to $9.00 per share.

There are 3 Hold Ratings, 3 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Akorn, Inc. (NASDAQ:AKRX) is Buy with a consensus target price of $14.40 per share, a potential 115.89% upside.

Some recent analyst ratings include

  • 10/17/2018-Akorn, Inc. (NASDAQ:AKRX) gets upgraded to Overweight by Piper Jaffray Companies with a price target of $9.00
  • 10/4/2018-Akorn, Inc. (NASDAQ:AKRX) gets upgraded to Buy by Craig Hallum
  • 8/23/2018-Akorn, Inc. (NASDAQ:AKRX) had its Buy rating reiterated by Deutsche Bank
  • 3/1/2018-Akorn, Inc. (NASDAQ:AKRX) had its Hold rating reiterated by William Blair
  • 4/25/2017-Akorn, Inc. (NASDAQ:AKRX) had its Buy ➝ Hold rating reiterated by Gabelli


  • On 1/25/2018 John N. Kapoor, Major Shareholder, sold 13,629 with an average share price of $32.67 per share and the total transaction amounting to $445,259.43.
  • On 11/21/2017 Brian Tambi, Director, sold 15,100 with an average share price of $33.35 per share and the total transaction amounting to $503,585.00.
  • On 8/4/2017 Brian Tambi, Director, sold 5,165 with an average share price of $33.37 per share and the total transaction amounting to $172,356.05.
  • On 8/3/2017 Bruce Kutinsky, COO, sold 40,000 with an average share price of $33.46 per share and the total transaction amounting to $1,338,400.00.
  • On 8/15/2016 Kenneth Abramowitz, Director, sold 2,691 with an average share price of $30.44 per share and the total transaction amounting to $81,914.04.
  • On 6/14/2016 Joseph Bonaccorsi, SVP, sold 6,500 with an average share price of $29.84 per share and the total transaction amounting to $193,960.00.
  • On 6/10/2016 Kenneth Abramowitz, Director, sold 14,675 with an average share price of $30.16 per share and the total transaction amounting to $442,598.00.

About Akorn, Inc. (NASDAQ:AKRX)
Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products, including Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. The company was founded in 1971 and is headquartered in Lake Forest, Illinois.

Recent Trading Activity for Akorn, Inc. (NASDAQ:AKRX)
Shares of Akorn, Inc. closed the previous trading session at 6.72 −0.77 10.35% with shares trading hands.